 |
Technical Support
(877) SEPAX-US, press 3  TechSupport@sepax-tech.com |
  |
Log in to Watch Webinar
MAb CEX HPLC Method Development
|
Recombinant monoclonal antibodies (mAbs) have become a very important segment of protein drug therapeutics. Post-translational modifications including glycosylation, oxidation, deamidation and incomplete C-terminal processing can contribute to antibody heterogeneity. Degradation reactions during manufacturing, formulation, and storage can also cause structural and functional changes in mAbs. It is important to characterize and evaluate the heterogeneities and monitor the stability of mAbs for shelf-life studies. Antibodix weak cation exchange (ABX WCX), Proteomix strong cation exchange (SCX) and Proteomix weak cation exchange (WCX) are applicable in separating antibodies with minor forms. These three resin surfaces are grafted different cation exchangers on a hydrophilic layer which offer different selectivity toward different antibodies.
More specifically, this webinar will cover:
|